Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05103046 · ClinicalTrials.gov registry record · Phase 1

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by 1200 Pharma.

Recruiting
Registry status
Phase 1
Development phase
68
Enrollment target
5
Study locations

NCT05103046: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by 1200 Pharma.

NCT05103046 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by 1200 Pharma. The registered enrollment target is 68 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (65% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05103046, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by 1200 Pharma.

RECRUITING
Registry status
Phase 1
Development phase
68 participants
Enrollment target
5
Study locations

Study Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG UCT-03-008

Study Locations (5)

California

  • UCLA - JCCC Clinical Research Unit - Los Angeles
  • Torrance Memorial - Torrance

Texas

  • Mary Crowley Cancer Research - Dallas
  • START (South Texas Accelerated Research Therapeutics) - San Antonio

Georgia

  • Winship Institute of Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2021-12-23
Est. Completion 2025-12-15
Phase Phase 1
1200 Pharma

2 total trials

What NCT05103046 shows while recruiting

NCT05103046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which UCT-03-008 is the first listed.

NCT05103046 lists 5 locations in 3 states (California, Texas, Georgia).

Frequently Asked Questions

What is clinical trial NCT05103046 about?

NCT05103046 is a clinical study titled "First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.

What is the current status of trial NCT05103046?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2021-12-23. Estimated completion is 2025-12-15.

What conditions does trial NCT05103046 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05103046?

The interventions under investigation include: UCT-03-008 (DRUG).

Who is sponsoring clinical trial NCT05103046?

This trial is sponsored by 1200 Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05103046 being conducted?

This trial has 5 study locations across California, Georgia, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05103046's enrollment target sits among peer trials

68 149th of 189 higher than 41 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05103046

Source: ClinicalTrials.gov NCT05103046, the US trial registry maintained by the National Library of Medicine. NCT05103046 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.